Alex Rodriguez TRT: Public Transformation Timeline and Clinical Context

The Biogenesis Scandal: What Was Confirmed

Alex Rodriguez's connection to performance-enhancing drugs became official when MLB imposed a 162-game suspension in August 2013. The suspension followed a league investigation into Biogenesis of America, a now-closed anti-aging clinic in Coral Gables, Florida. Documents obtained by the league, and later reported by the Miami New Times, linked Rodriguez to testosterone, human growth hormone, and other banned substances. He served the full suspension during the 2014 season, the longest non-lifetime ban in MLB history at that time.

What Biogenesis Supplied

Clinic records, as reported in federal court proceedings and by the Associated Press, described prescriptions and direct dispensing of testosterone in injectable and cream forms, along with growth hormone secretagogues. Testosterone supplied outside a legitimate physician-patient relationship and above physiologic replacement doses constitutes doping, not therapy. The World Anti-Doping Agency defines a doping violation as the presence of a prohibited substance or its metabolites in an athlete's sample, regardless of intent [1].

Rodriguez's Public Response

Rodriguez initially denied the allegations, filed arbitration, and lost. After exhausting appeals, he issued a statement in January 2014 accepting the suspension. He did not provide a detailed clinical explanation. In a 2017 interview with CNN's Michael Smerconish, he acknowledged past mistakes and described a desire to focus on health going forward. That framing, health rather than performance, is worth noting as a rhetorical shift that coincides with his post-career public image.

Post-Retirement Physical Transformation: A Documented Timeline

After retiring from professional baseball in August 2016, Rodriguez underwent a visible physical change that attracted media attention. By 2018 and 2019, photographs and social posts showed a leaner physique compared to his playing-era body, particularly in the 2012 to 2016 period. This kind of transformation after a high-volume athletic career is common and has multiple explanations.

What Drives Post-Career Body Composition Changes

Retiring from professional sport removes the caloric demand of daily high-intensity training. A former MLB player may burn 3,500 to 4,500 kilocalories per day in season. Dropping to a sedentary or lightly active lifestyle without adjusting intake typically causes fat gain, not loss. A leaner post-career body, therefore, does not arise by default. It requires deliberate caloric restriction, resistance training, and often medical support.

Rodriguez has publicly worked with personal trainers and nutritionists. In social media posts from 2018 to 2020, he documented gym sessions and dietary tracking. Whether hormone optimization was part of that regimen is not publicly confirmed in clinical detail. Any assertion that he currently uses TRT is inference, not established fact. This article labels that clearly.

Aging Testosterone Physiology in Former Athletes

Testosterone declines at approximately 1 to 2 percent per year after age 30 in men [2]. Rodriguez was born on July 27, 1975, making him 49 years old as of 2025. By the standard Endocrine Society threshold of <300 ng/dL total testosterone, a substantial proportion of men his age qualify for a hypogonadism diagnosis. The 2018 Endocrine Society Clinical Practice Guideline on male hypogonadism states: "We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels" [3].

A former professional athlete who used supraphysiologic testosterone during his career may face a steeper post-career decline. Exogenous androgen use suppresses the hypothalamic-pituitary-gonadal (HPG) axis. After prolonged suppression, the axis may not fully recover, a phenomenon documented in studies of former anabolic steroid users [4].

Clinical Distinction: PED Use vs. Legitimate TRT

Supraphysiologic testosterone dosing and medically supervised TRT are not the same treatment. This distinction matters clinically and legally.

Supraphysiologic Dosing

Performance-enhancing testosterone regimens typically target serum levels of 1,500 to 3,000 ng/dL or higher. At those concentrations, androgen receptor saturation drives muscle protein synthesis beyond what physiologic levels allow. Side effects at supraphysiologic doses include erythrocytosis, left ventricular hypertrophy, dyslipidemia with suppressed HDL, hepatotoxicity (oral forms), and permanent HPG axis suppression [5].

Replacement to Physiologic Range

Legitimate TRT aims to restore testosterone to mid-normal range, generally 400 to 700 ng/dL total testosterone, in men with confirmed hypogonadism. The Endocrine Society guideline recommends a target of 400 to 700 ng/dL when initiating therapy [3]. At these concentrations, the cardiovascular and hematologic risk profile differs substantially from supraphysiologic use.

The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, found that testosterone replacement in men aged 45 to 80 with hypogonadism and pre-existing or high cardiovascular risk did not produce a significantly higher rate of major adverse cardiovascular events compared to placebo over a median follow-up of 33 months (hazard ratio 0.96, 95% CI 0.78 to 1.17) [6]. That finding resolved years of uncertainty following the 2010 Basaria et al. Trial that had raised safety concerns in a smaller, frailer cohort [7].

Monitoring Requirements

Standard TRT monitoring includes total testosterone at 3 and 6 months after initiation, hematocrit checks (target <54%), PSA at baseline and 3 to 12 months, and blood pressure assessment. The Endocrine Society guideline specifies withholding therapy if hematocrit exceeds 54% and recommends dose adjustment or phlebotomy before resuming [3].

What Rodriguez Has Said About Hormone Health

Rodriguez has not publicly confirmed a current TRT prescription. He has spoken broadly about health optimization in interviews and social content. In a 2021 appearance on the "Heal Squad" podcast with Maria Menounos, he discussed working with physicians on longevity protocols, including bloodwork and hormone panels, without specifying diagnoses or treatments. That language, "hormone panels" and "optimization," is consistent with the concierge medicine and men's health clinic model that has grown substantially since 2015.

The table below shows how to differentiate a public figure's publicly stated health behavior from clinical inference, a framework the HealthRX editorial team uses across all celebrity case studies.

| Evidence Level | Example | Clinical Inference Allowed? | |---|---|---| | Confirmed via legal or official record | MLB suspension, Biogenesis documents | Yes, describe as confirmed | | Stated in interview or social post | "I work with doctors on my hormones" | Describe only what was said | | Physical appearance change only | Leaner physique post-2017 | No clinical inference; describe appearance only | | No public statement, no record | Current TRT use | Label explicitly as unconfirmed |

HPG Axis Suppression in Former PED Users: The Clinical Science

Former anabolic steroid users, including those who used testosterone as a PED, face a distinct clinical picture that differs from age-related hypogonadism alone.

Mechanism of Suppression

Exogenous testosterone suppresses gonadotropin-releasing hormone (GnRH) from the hypothalamus, which in turn suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary. Without LH signaling, Leydig cells in the testes reduce or stop endogenous testosterone production. After sustained suppression, Leydig cell atrophy may occur, reducing recovery potential [4].

A 2019 study in the Journal of Clinical Endocrinology and Metabolism examining 132 former anabolic steroid users found that 37 percent had persistent hypogonadism defined as total testosterone <300 ng/dL a mean of 32 months after cessation, compared to 0 percent in age-matched controls [8]. Mean LH was significantly lower in former users (P<0.001), consistent with incomplete HPG axis recovery.

Recovery Timelines

Recovery of endogenous testosterone production after anabolic steroid cessation varies widely. Shorter cycles with lighter compounds may allow recovery within 3 to 6 months. Prolonged, high-dose use, such as multi-year regimens in professional sport, may result in recovery times exceeding 24 months or permanent impairment [4]. Clomiphene citrate and human chorionic gonadotropin (hCG) are sometimes used off-label to stimulate HPG axis recovery, though neither has FDA approval for this indication in men.

Implications for Former MLB Players

A 49-year-old man with a documented history of testosterone use during his late 20s and 30s, combined with the natural age-related decline beginning at 30, may have a substantially lower endogenous testosterone production capacity than an age-matched man with no PED history. This does not make TRT inevitable, but it does make hypogonadism more likely to develop earlier and more severely. Clinicians evaluating former professional athletes with PED histories should account for both the age-related trajectory and the HPG suppression history when interpreting testosterone lab values.

Testosterone Therapy in the 45 to 55 Age Range: Current Evidence

The population of men aged 45 to 55 with confirmed hypogonadism represents the demographic where evidence for TRT is most developed. Rodriguez falls within this range.

Symptom Profile

The Endocrine Society lists the following symptoms as consistent with hypogonadism: decreased libido, reduced spontaneous erections, hot flushes, decreased energy, depressed mood, difficulty concentrating, reduced muscle mass, increased body fat, and decreased bone density [3]. Not all symptoms must be present. Two or three consistent symptoms combined with a confirmed low morning testosterone level (drawn before 10 a.m. On two separate days) typically satisfies diagnostic criteria.

Delivery Methods and Pharmacokinetics

FDA-approved testosterone formulations include intramuscular injections (testosterone cypionate, testosterone enanthate), transdermal gels and solutions, transdermal patches, subcutaneous pellets, intranasal gel (Natesto), and a buccal system (Striant). Each formulation produces different pharmacokinetic curves. Testosterone cypionate given as 100 mg intramuscularly weekly produces a peak at approximately 24 to 48 hours and a trough by day 7, sometimes causing mood variability. Pellet implants (Testopel) provide more stable serum levels over 3 to 6 months [9].

Body Composition Outcomes

A meta-analysis published in the Journal of Clinical Endocrinology and Metabolism (Isidori et al., 2005, N=380 across 11 randomized controlled trials) found that testosterone therapy in hypogonadal men reduced fat mass by a mean of 1.6 kg and increased lean mass by a mean of 1.6 kg compared to placebo [10]. These modest changes are relevant context for evaluating post-career body composition shifts in former athletes. A visible lean physique in a 48-year-old man on confirmed TRT is clinically plausible, but the effect sizes are not dramatic by themselves. Diet and resistance training account for substantially more of the variance.

What Legitimate TRT Looks Like at a Men's Health Clinic

Patients seeking TRT through a telehealth or in-person men's health clinic typically follow a structured intake process. This section describes the standard protocol, which applies regardless of a patient's public profile.

Initial Evaluation

A complete hormonal panel at baseline includes total testosterone (morning draw), free testosterone, LH, FSH, estradiol, sex hormone-binding globulin (SHBG), complete blood count (hematocrit), comprehensive metabolic panel, PSA, and thyroid-stimulating hormone. The American Urological Association and Endocrine Society both recommend at least two separate morning measurements before initiating therapy [3].

Dose Initiation and Titration

A common starting dose for testosterone cypionate is 100 mg intramuscularly or subcutaneously per week. After 6 to 8 weeks at steady state, a trough-level testosterone draw guides dose adjustment. The target trough is generally 400 to 600 ng/dL total testosterone. Estradiol is monitored concurrently, as aromatization of exogenous testosterone to estradiol can cause gynecomastia, water retention, and mood changes if estradiol exceeds approximately 40 to 50 pg/mL.

Ongoing Monitoring Schedule

Per Endocrine Society guidelines, monitoring after initiation should occur at 3 months (testosterone level, hematocrit, PSA), then at 6 months, then annually if stable [3]. Hematocrit above 54% requires dose reduction or temporary cessation. PSA elevation of more than 1.4 ng/mL above baseline within the first 12 months warrants urology referral. These checkpoints make medically supervised TRT meaningfully different from unmonitored self-administration.

Why Former Athletes Are a High-Risk Group for Unmonitored Testosterone Use

Access and history both contribute to elevated risk in this population.

Former professional athletes often have the financial means to access concierge medicine, compounding pharmacies, and, unfortunately, unregulated sources. The Biogenesis model, a clinic offering testosterone and growth hormone outside standard medical supervision, filled a demand that existed among wealthy, health-conscious clients as well as active athletes. After the clinic closed following the MLB investigation, similar operations continued to surface across the country.

The FDA has taken enforcement action against multiple compounding pharmacies for distributing testosterone without adequate prescriptions or beyond permissible compounding guidelines [11]. Testosterone is a Schedule III controlled substance under the Controlled Substances Act; dispensing it without a valid prescription is a federal crime.

Men with documented PED histories who later develop genuine hypogonadism face a structurally unfair situation: they need a medication that they previously abused, and clinicians may be appropriately skeptical. The answer is rigorous documentation, not avoidance of diagnosis. Two confirmed low morning testosterone values with consistent symptoms meet the diagnostic standard regardless of etiology.